Microbiota can be recognized by the human immune system,trigger specific immune responses,and play a significant role in the onset and progression of diseases through intricate regulatory mechanisms.The tumor microenvironment comprises the peritumoral extracellular matrix,immune cells,tumor-associated fibroblasts,and endothelial cells,among others.In this context,the tumor immune microenvironment,characterized by immune cells,significantly influences cancer progression and treatment.Notably,the tumor immune microenvironment is closely associated with the tumor microbiota.The presence of respiratory microbiota is correlated with the typing and staging of non-small cell lung cancer.This study investigated the mechanisms by which respiratory microbiota affect innate and adaptive immune cells within the tumor immune microenvironment and explored the role of respiratory microbiota in the immunotherapy of non-small cell lung cancer.The aim was to identify potential biomarkers that could enhance the diagnosis and treatment of non-small cell lung cancer.

Microbiota can be recognized by the human immune system,trigger specific immune responses,and play a significant role in the onset and progression of diseases through intricate regulatory mechanisms.The tumor microenvironment comprises the peritumoral extracellular matrix,immune cells,tumor-associated fibroblasts,and endothelial cells,among others.In this context,the tumor immune microenvironment,characterized by immune cells,significantly influences cancer progression and treatment.Notably,the tumor immune microenvironment is closely associated with the tumor microbiota.The presence of respiratory microbiota is correlated with the typing and staging of non-small cell lung cancer.This study investigated the mechanisms by which respiratory microbiota affect innate and adaptive immune cells within the tumor immune microenvironment and explored the role of respiratory microbiota in the immunotherapy of non-small cell lung cancer.The aim was to identify potential biomarkers that could enhance the diagnosis and treatment of non-small cell lung cancer.

Objective To evaluate the efficacy of itraconazole combined with glucocorticosteroid in allergic bronchopulmonary aspergillosis.Methods The clinical characteristics and data of 11 allergic bronchopulmonary aspergillosis patients treated with itraconazole combined with glucocorticosteroid were retrospectively collected before treatment and two months after treatment.Then the clinical characteristics and data before and after treatment were compared to evaluate the efficacy of the treatment.Results The symptoms and signs got better after two months' treatment.C reactive protein,IgE and eosinophile granulocyte count after two months' treatment were significantly lower than that before treatment [(7 ±2) mg/L vs.(42± 13) mg/L,(742 ± 236) kU/L vs.(1 685 ±477) kU/L,(343 ± 112) × 106/L vs.(1 925 ± 318) × 106/L],and forced expired volume in one second percentage of predicted and arterial partial pressure of oxygen after two months' treatment were significantly higher than those before treatment [(77.5 ± 8.6)％ vs.(32.4 ± 9.1)％ and (81 ± 12) mmHg (1 mmHg =0.133 kPa) vs.(53 ± 6) mmHg],there were statistical differences (P ＜ 0.01 or ＜ 0.05).The inflammatory exudates resolved as demonstrated in pulmonary CT scan.Conclnsion Itraconazole combined with glucocorticosteroid can effectively neat allergic bronchopulmonary aspergillosis.